Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645466 | 0.85 | POLB (0.53) | HTTSMN1; SMN2ALDH1A1PKMLMNA | |
| SCHEMBL643003 | 0.79 | LMNA (0.40) | SMN1; SMN2ALDH1A1PKMLMNAHPGD | |
| SCHEMBL2338199 | 0.72 | HPGD (0.76) | SMN1; SMN2ALDH1A1LMNAHPGDL3MBTL1 | |
| SCHEMBL30041059 | 0.72 | HPGD (0.62) | SMN1; SMN2LMNAHPGDL3MBTL1MAPT | |
| SCHEMBL23731587 | 0.71 | HPGD (0.55) | SMN1; SMN2ALDH1A1LMNAHPGDL3MBTL1 | |
| SCHEMBL24984300 | 0.70 | HPGD (0.64) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL30892467 | 0.70 | HPGD (0.64) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL16015342 | 0.70 | LMNA (0.67) | SMN1; SMN2LMNAHPGDL3MBTL1MAPT | |
| SCHEMBL28448203 | 0.70 | HPGD (0.71) | SMN1; SMN2ALDH1A1LMNAHPGDL3MBTL1 | |
| SCHEMBL24983425 | 0.69 | HPGD (0.84) | SMN1; SMN2ALDH1A1LMNAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | HTT 1560/4885SMN1; SMN2 2653/4885ALDH1A1 1370/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | HTT 1560/4885SMN1; SMN2 2653/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.